Critical Survey: Vanda Pharmaceuticals (NASDAQ:VNDA) versus Perrigo (NYSE:PRGO)

Perrigo (NYSE:PRGO – Get Free Report) and Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, earnings, profitability and institutional ownership.

Institutional & Insider Ownership

95.9% of Perrigo shares are owned by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 0.4% of Perrigo shares are owned by insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Perrigo and Vanda Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Perrigo 2 3 1 0 1.83
Vanda Pharmaceuticals 1 2 6 0 2.56

Perrigo currently has a consensus target price of $18.50, suggesting a potential upside of 13.10%. Vanda Pharmaceuticals has a consensus target price of $13.50, suggesting a potential upside of 247.49%. Given Vanda Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than Perrigo.

Volatility & Risk

Perrigo has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.

Valuation and Earnings

This table compares Perrigo and Vanda Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Perrigo $4.25 billion 0.53 -$1.43 billion ($12.76) -1.28
Vanda Pharmaceuticals $216.10 million 1.09 -$220.47 million ($4.62) -0.84

Vanda Pharmaceuticals has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Perrigo and Vanda Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Perrigo -43.27% 12.39% 4.07%
Vanda Pharmaceuticals -119.87% -62.70% -37.53%

Summary

Vanda Pharmaceuticals beats Perrigo on 9 of the 14 factors compared between the two stocks.

About Perrigo

(Get Free Report)

Perrigo is a global consumer healthcare company that develops, manufactures and markets over-the-counter medicines and other self-care products. Its offerings include treatments for allergies, coughs and colds, pain and digestive health, as well as skin care, oral care and infant nutrition products. The company supplies both its own consumer brands and store-brand products, which retailers sell under their own labels. Perrigo serves customers primarily in North America and Europe through retail and other healthcare channels.

About Vanda Pharmaceuticals

(Get Free Report)

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders and other conditions. Headquartered in Washington, D.C., the company was founded in 2003. Its commercial products include Fanapt (iloperidone), approved in the United States for schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder, and Hetlioz (tasimelteon), used to treat non-24-hour sleep-wake disorder and nighttime sleep disturbances associated with Smith-Magenis syndrome.

Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.